Publication: Aplicación de ingeniería financiera para la curación de enfermedades
Loading...
Official URL
Full text at PDC
Publication Date
2017
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
En este trabajo se estudia un método propuesto recientemente Fernández, Stein, y Lo (2012), denominado megafondo, con el cuál se incrementa el número de proyectos dentro de una misma entidad y se diversifica la cartera. De este modo, se pueden emitir distintos tipos de títulos para atraer a mayor cantidad de inversores, consiguiendo el capital necesario para conseguir la mencionada diversificación.
Description
UCM subjects
Unesco subjects
Keywords
Citation
Bogdan, Boris y Villiger, Ralph (2007): Valuation in Life Sciences. Springer. Berlin.
DiMasi, J. A. (2001): “Risks in new drug development: Approval success rates for investigational drugs”. Clinical Pharmacology & Therapeutics, 69(5) Págs.: 297-307.
DiMasi, J.A. et al. (2010): “Trends in risk associated with new drug development: success rates for investigational drugs”. Clinical Pharmacology & Therapeutics, 87 Págs.: 272–277.
European Medicines Agency (2017) Accedido el 27 de abril. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000
029.jsp&mid=WC0b01ac0580b18a41 .
Fagnan, David E.; Fernández, José M.; Lo, Andrew W. y Stein, Roger M. (2013): “Can Financial Engineering Cure Cancer?”. American Economic Review: Papers & Proceedings, 103(3). Págs.: 406-411 https://ssrn.com/abstract=2203203 .
Fagnan, David E.; Gromatzky, Austin A.; Stein, Roger M.; Fernández, José M. y Lo, Andrew W. (2014): “Financing drug discovery for orphan diseases”. Drug Discovery Today. Vol 19, nº 5. Págs.: 533-538 https://doi.org/10.1016/j.drudis.2013.11.009 .
Fagnan, David E.; Gromatzky, Austin A.; Stein, Roger M.; Fernández, José M. y Lo, Andrew W. (2014): Supplemental Information and Parameters for “Financing Drug Discovery for Orphan Diseases” https://doi.org/10.1016/j.drudis.2013.11.009 .
Fernández, José M.; Stein, Roger M. y Lo, Andrew W. (2012): “Commercializing biomedical research through securitization techniques”. Nature Biotech. Vol 30, nº10. Págs.: 964-975 http://www.nature.com/nbt/journal/v30/n10/full/nbt.2374.html .
Fernández, José M.; Stein, Roger M. y Lo, Andrew W. (2012): Supplementary Information for “Commercializing biomedical research through securitization techniques” http://www.nature.com/nbt/journal/v30/n10/full/nbt.2374.html .
Fernández, José M.; Stein, Roger M. y Lo, Andrew W. (2015): “Frequently Asked Questions about Megafunds” http://alo.mit.edu/wp-content/uploads/2015/10/FAQ20151005.pdf .
Food and Drug Administration (2017) Orphan Drug Product Designation Database. Accedido el 1-mayo-2017. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ .
Food and Drug Administration (2017) Novel Drug Approvals. Accedido el 1-mayo-2017.
-2015: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302.htm .
-2016: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm483775.htm .
-2017: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm .
Harrington, Scott E. (2009). “Cost of Capital for Pharmaceutical, Biotechnology, and Medical Device Firms” http://dx.doi.org/10.2139/ssrn.1512938
Julián, R y Mascareñas, J (2014): “La Financiación de Proyectos (Project Finance)”. Monografías de Juan Mascareñas sobre Finanzas Corporativas 46. Disponible en: http://ssrn.com/abstract=2407394 .
Kaitin, K.I. and DiMasi, J.A. (2010): “Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009”. Clinical Pharmacology and Therapeutics. Vol. 89, nº2. Págs.: 183–188.
Kellogg, David; Charnes, John y Demirer, Riza (1999): “Valuation of a Biotechnology Firm: An application of real-options methodology” 3rd Annual Real Options Conference. http://www.realoptions.org/papers1999/Kellogg.pdf .
Kim, Esther S., Lo, Andrew W. (2016): “Business models to cure rare disease: a case study of solid biosciences”. Journal of Investment Management. Vol. 14, nº4. Págs.: 87-101 https://ssrn.com/abstract=2864709 .
Mascareñas, Juan (2016): “La valoración de un proyecto biotecnológico como una opción real compuesta” En Monografías de Juan Mascareñas sobre Finanzas. http://dx.doi.org/10.2139/ssrn.2316655 .
Mathieu, M. (2013): PAREXEL Biopharmaceutical Statistical Sourcebook 2013–2014. Needham, MA: Barnett International.
Orfali, M. et al. (2012): “Raising orphans: how clinicaldevelopment programs of drugs for rare and common diseases are different”. Clinical Pharmacology and Therapeutics. Vol. 92, nº 2.Págs.: 262–264.
Ou, S. (2011): Corporate Default and Recovery Rates, 1920–2010. Moody’s Investors Service.
Paul, S.M. et al. (2010): “How to improve R&D productivity: the pharmaceutical industry’s grand challenge”. Nature Reviews Drug Discovery. Vol. 9, nº3. Págs.: 203–214. https://www.scopus.com/record/display.uri?eid=2-s2.0-77649234756&origin=inward&txGid=58B7ED4961A5FE4B12C124C3ECAFD02E.wsnAw8kcdt7IPYLO0V48gA%3a36 .
Seoane-Vasquez, Enrique; Rodriguez-Monguio, R; Szeinbach, Sheryl L. y Visaria, J. (2008): “Incentives for orphan drug research and development in the United States”. Orphanet Journal of Rare Diseases. 3, 33. https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-33 .
Thomson Reuters. (2012): “The economic power oforphan drugs”. https://www.thomsonreuters.com/content/dam/openweb/documents/pdf/pharma-lifesciences/white-paper/1001450.pdf .